IP Library › Granted Patent US 10,301,288
Granted Patent B2
US 10,301,288 · App. 15/830,996 · Granted May 28, 2019

Kinase inhibitors

Inventor: Matthew Colin Thor Fyfe (London, GB)
Assignee: Topivert Pharma Limited
C07D403/12A61K31/4439A61K31/506A61K31/5377A61K31/675A61K45/06C07D401/12C07D401/14C07F9/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,301,288
App. No.
15/830,996
Granted
May 28, 2019
Kind
B2
Abstract

There are provided compounds of formula (III), or a salt or protected derivative thereof, wherein Z 2 represents a structural fragment of formula (V), wherein R 1 , R a , R b , X and Y have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Claims (44)

1. A compound of formula (III),

or a salt or protected derivative thereof, wherein Z 2 represents a structural fragment of formula (V),

wherein:

X represents CH or N,

Y represents NR 2 R 3 ;

R a and R b , together with the C-atoms to which they are attached, form a fused phenyl ring that is optionally substituted by one or more substituents selected from the group consisting of C 1-3 alkyl, C 1-3 haloalkyl, cyano and halo,

or one of R a and R b represents H, halo, cyano, C 1-3 alkyl or C 1-3 haloalkyl and the other independently represents halo, cyano, C 1-3 alkyl or C 1-3 haloalkyl

or R a and R b together represent C 3-5 n-alkylene, which alkylene group is optionally substituted by one or more methyl substituents and/or which alkylene group optionally contains one C—C double bond between two C-atoms of the n-alkylene chain;

R 1 is selected from the group consisting of hydrogen, OH, halogen, CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 0-3 alkylene-C 3-6 cycloalkyl, C 0-3 alkylene-O—C 1-3 alkylene-C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 hydroxyalkyl, C 0-3 alkylene-SO 2 C 1-3 alkyl, C 0-3 alkylene-SO 2 NR 4 R 5 , and C 0-3 alkylene-NR 6 R 7 and C 0-3 alkylene-NCOR 6 R 7 ;

one of R 2 and R 3 represents —[C 2-4 alkylene-O] 1-12 —[C 2-4 alkylene]-R 2a and the other of R 2 and R 3 is selected from the group consisting of H, C 1-8 alkyl, C 0-6 alkylene aryl, C 0-6 alkylene heteroaryl, —[C 2-4 alkylene-O] 0-12 —[C 2-4 alkylene]-R 2a , C 0-6 alkylene-4-10 membered heterocycle, and C 0-3 alkylene-O—C 0-6 alkylene-4-10 membered heterocycle with the proviso that when the said heterocycle is linked through nitrogen there are at least two C-atoms in the alkylene chain that links that nitrogen atom to the essential O atom of the substituent, wherein independently each alkyl or alkylene group optionally bears 1 oxo substituent, and optionally one or two carbon atoms in the alkyl or alkylene chain may each be replaced by a heteroatom selected from the group consisting of O, N and S(O) p , such that when said alkyl or alkylene comprises an amine said amino group is a tertiary amine,

wherein each 4-10 membered heterocycle is optionally substituted by 1 or 2 groups independently selected from the group consisting of halo, OH, C 1-6 alkyl, C 1-4 haloalkyl, C 0-3 alkylene-O—C 0-6 alkyl, C 0-3 alkylene-O—C 1-3 haloalkyl, C 0-6 alkylene aryl, C 0-3 alkylene-O—C 0-3 alkylene aryl, C 0-6 alkylene heteroaryl, C 0-3 alkylene-O—C 0-3 alkylene heteroaryl, C(O)C 1-6 alkyl, SO 2 NR 8 R 9 , and C 0-3 alkylene-NR 8 R 9 , C 0-3 alkylene-NR 8 SO 2 R 9 and C 0-3 alkylene-NR 8 C(O)R 9 ;

R 2a represents OR 2b or N(R 2c )R 2d ;

R 2b to R 2d independently represent H or C 1-4 alkyl optionally substituted by one or more halo atoms, or R 2c and R 2d together represent

C 3-6 n-alkylene,

C 4-5 n-alkylene interrupted between C2 and C3 by —O— or —N(R 2e )— or

C 6 n-alkylene interrupted between C2 and C3, or between C3 and C4, by —O— or —N(R 2e )—,

any of which n-alkylene groups are optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, oxo, C 1-4 alkyl and C 1-4 alkoxy;

R 2e represents H or C 1-6 alkyl optionally substituted by one or more substituents selected from the group consisting of halo and hydroxy;

R 4 is H or C 1-4 alkyl;

R 5 is H or C 1-4 alkyl,

R 6 is H or C 1-4 alkyl, C(O)C 1-3 alkyl and SO 2 C 1-3 alkyl;

R 7 is H or C 1-4 alkyl, C(O)C 1-3 alkyl and SO 2 C 1-3 alkyl;

R 8 is H or C 1-4 alkyl,

R 9 is H or C 1-4 alkyl and

p is 0, 1 or 2,

wherein said protected derivative is a compound in which a H-atom of the NH 2 group of the compound of formula (III) is replaced by:

R′—C(O)—, wherein R′ is H, C 1-8 alkyl, phenyl or benzyl, which latter two groups are optionally substituted by one or more groups selected from the group consisting of halo, hydroxy, methyl and methoxy; or

R″—O—C(O)—, wherein R″ is tert-butyl, phenyl, benzyl or fluorenyl, which latter three groups are optionally substituted by one or more groups selected from the group consisting of halo, hydroxy, methyl and methoxy.

2. A compound according to claim 1 , wherein:

R a and R b , together with the C-atoms to which they are attached, form a fused phenyl ring that is unsubstituted;

X represents CH or N;

R 1 represents ethynyl or OCH 3 ;

Y represents NR 2 R 3 ;

R 2 represents —(CH 2 CH 2 O) 2-4 CH 3 ; and

R 3 is H,

wherein the protected derivative is a compound in which a H-atom of the NH 2 group of formula (III) is replaced by:

R′—C(O)—, wherein R′ is H, C 1-8 alkyl, phenyl or benzyl, which latter two groups are optionally substituted by one or more groups selected from the group consisting of halo, hydroxy, methyl and methoxy, or

R″—O—C(O)—, wherein R″ is tert-butyl, phenyl, benzyl or fluorenyl, which latter three groups are optionally substituted by one or more groups selected from the group consisting of halo, hydroxy, methyl and methoxy.

3. A compound according to claim 1 which has the following structure:

(3-((4-((4-aminonaphthalen-1-yl)oxy)pyrimidin-2-yl)amino)-5-ethynyl-N-(2-(2-(2-methoxyethoxy)ethoxy)ethyl)benzamide),

or a salt thereof.

4. A compound according to claim 1 which has the following structure:

(tert-butyl (4-((2-((3-ethynyl-5-((2-(2-(2-methoxyethoxy)ethoxy)ethyl)carbamoyl)phenyl)-amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)carbamate),

or a salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: TOPIVERT PHARMA LIMITED
To: OXULAR ACQUISITIONS LIMITED
Reel/Frame 054610/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: RESPIVERT LIMITED
To: TOPIVERT PHARMA LIMITED
Reel/Frame 047725/0470 →
Priority Claims (2)
GB 1314700.4 · Aug 16, 2013 · national
GB 1322684.0 · Dec 20, 2013 · national
Continuity (4)
Division 15207915 · Jul 12, 2016
Continuation 14775924
Provisional Application 61782793 · Mar 14, 2013
Related Publication 20180086741A1 · Mar 29, 2018